Mariner LLC Has $64,000 Stake in ProKidney Corp. (NASDAQ:PROK)

Mariner LLC reduced its stake in ProKidney Corp. (NASDAQ:PROK) by 29.5% during the fourth quarter, HoldingsChannel reports. The firm owned 38,119 shares of the company’s stock after selling 15,937 shares during the quarter. Mariner LLC’s holdings in ProKidney were worth $64,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in PROK. Geode Capital Management LLC lifted its stake in ProKidney by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 2,231,930 shares of the company’s stock valued at $3,773,000 after purchasing an additional 27,996 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of ProKidney by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 759,787 shares of the company’s stock valued at $1,284,000 after acquiring an additional 10,069 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of ProKidney during the 4th quarter valued at $961,000. Bank of New York Mellon Corp grew its position in ProKidney by 20.6% during the 4th quarter. Bank of New York Mellon Corp now owns 229,770 shares of the company’s stock worth $388,000 after acquiring an additional 39,275 shares during the last quarter. Finally, Barclays PLC increased its holdings in ProKidney by 17.4% in the 4th quarter. Barclays PLC now owns 171,797 shares of the company’s stock worth $290,000 after purchasing an additional 25,476 shares in the last quarter. 51.59% of the stock is owned by institutional investors.

Insider Activity at ProKidney

In other news, insider Control Empresarial De Capital purchased 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 16th. The shares were acquired at an average cost of $0.75 per share, with a total value of $75,000.00. Following the purchase, the insider now owns 73,430,330 shares in the company, valued at $55,072,747.50. This represents a 0.14 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have purchased 1,787,716 shares of company stock worth $1,175,419 in the last quarter. Company insiders own 41.49% of the company’s stock.

ProKidney Trading Up 3.1 %

Shares of PROK stock opened at $0.72 on Friday. The business’s 50-day moving average price is $0.84 and its 200-day moving average price is $1.41. ProKidney Corp. has a 12 month low of $0.46 and a 12 month high of $4.44. The firm has a market capitalization of $211.15 million, a price-to-earnings ratio of -1.31 and a beta of 1.50.

ProKidney (NASDAQ:PROK) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $0.08 million during the quarter. On average, sell-side analysts predict that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.